Quick Acting Antibiotic Lends Promise To Destiny's Future

Destiny Pharma's US NIAID-funded clinical study yields positive results for the novel quick-acting antibacterial exeporfinium chloride.

Destiny Pharma of the UK is developing XF-73 (exeporfinium chloride), an antibiotic for the prevention of post-surgical Staphylococcal infection, a new indication. The FDA granted the product Qualified Infectious Disease Product (QIDP) status last November. Earlier this year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, sponsored and funded a Phase I/IIa trial to study Staphylococcus aureus decolonization (i.e. the clearance of the bacteria from the nostrils of carriers). (Also see "'Rapid Kill' Antibiotic Awaits US Data For Blanket Decolonization Prior To Surgery " - Scrip, 3 March, 2016.)

In the US trial, XF-73 was shown to be safe and demonstrated a significant anti-staphylococcal effect after just 1 day...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By 

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip